Pfizer (PFE) Tops Q1 EPS by 12c; Boosts FY16 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/7/2026
- Equities poised for best week since April as payrolls surprise eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Oil gains on pending Iran-Oman deal over Hormuz
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Citi says buy the pullback in memory stocks as upcycle is still in early innings
- Stocks close lower as investors eye Mideast talks, earnings
- The Trade Desk Inc. (TTD) Tops Q2 EPS by 16c, Misses on Revenue; Offers Weak Q3 Revenue Guidance
- Apollo to acquire easyJet for £5.7B in cash deal
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Pfizer (PFE) Target Increases at BMO Capital Following a Good Quarter
May 4, 2016 6:59 AM EDTBMO Capital analyst, Alex Arfaei, raised his PT on Pfizer (NYSE: PFE) to $40 (from $39) but admitted that much of the top-line beat was driven by more selling days in 1Q16 vs. 1Q15. Pfizers major growth drivers (e.g., Prevnar, Ibrance, Xeljanz, and Eliquis) all... More
